Mauna Kea Technologies : 2021 : année du décollage
>La publication anticipée confirme la recovery - Concomitamment à notre forum, Mauna Kea Technologies a annoncé son chiffre d’affaires estimé pour le T4 2020, pratique que la société a mis en place depuis quelques trimestres du fait de la volatilité dans ses opérations induite par la crise COVID-19. Le moins que l’on puisse dire est que le niveau d’activité est bon, voire très bon. La société s’attend à un quatrième trimestre en hausse de 30 à 36%, soit 2.2 à 2.3 M€, ...Mauna Kea Technologies is a global medical device company based in France. Co. is focused on innovations in the field of endomicroscopy (microscopic imaging during endoscopy procedures). Co. is predominately active in the advent of optical biopsy. Co. researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Co.'s flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Co. has marketing authorizations in Thailand, United Kingdom, U.S., Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.